Cardiac Amyloidosis: On the Road
Multimodality Imaging for the Evaluation & Management of Cardiac Amyloidosis Live Program
Saturday, December 11, 2021
Credits: Earn 2.75* AMA PRA Category 1 Credits™
Fadi Hage, MD, MASNC
|December 11, 2021: Multimodality Imaging for the Evaluation & Management of Cardiac Amyloidosis|
|7:55 am||Welcome||Fadi Hage, MD, MASNC|
|8:00 am||Cardiac Amyloid Case Presentation||Stephen Clarkson, MD|
|8:10 am||When to suspect cardiac amyloid?||Carrie Lenneman, MD|
|8:30 am||Echocardiographic imaging for cardiac amyloid||Riem Hawi, MD|
|8:50 am||MRI for cardiac amyloid||Steven Lloyd, MD|
|9:10 am||Discussion and Q&A||Fadi Hage, MD, MASNC and faculty|
|9:30 am||Cardiac Amyloid Case Presentation||Nikky Bardia, MD|
|9:40 am||Technetium-99m Pyrophosphate (PYP) Imaging for cardiac amyloid||Fadi Hage, MD, MASNC|
|10:00 am||Pathways for management of patients with equivocal PYP imaging||Pradeep Bhambhvani, MD|
|10:20 am||Cardiac Amyloid Case Presentation||Jordan Gunn, MD|
|10:30 am||Clinical management of cardiac amyloid||Jose Tallaj, MD|
|10:50 am||Discussion and Q&A||Fadi Hage, MD, MASNC and faculty|
|11:05 am||Wrap up||Fadi Hage, MD, MASNC|
The Cardiac Amyloidosis: On the Road programs will:
Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM.
Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM.
Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.
Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings.
Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
Participants of these programs will be able to:
Describe amyloidosis, including specific types, cardiac features and disease burden.
Identify barriers to identification and diagnosis of patients suspected of ATTR.
Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis.
Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report.
Demonstrate understanding of current treatments for patients with ATTR-CM.
If you have any questions about registration, please contact firstname.lastname@example.org
These programs are supported by educational grants from Pfizer.
Back to top